Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.12 USD
Change Today -0.0331 / -22.03%
Volume 61.3K
ILIU On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

interleukin genetics inc (ILIU) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - $0.46
52 Week Low
12/15/14 - $0.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

interleukin genetics inc (ILIU) Related Businessweek News

No Related Businessweek News Found

interleukin genetics inc (ILIU) Details

Interleukin Genetics, Inc. focuses on the development and commercialization of personalized health products that help individuals to improve and maintain their health through preventive measures in the United States. It offers PerioPredict, a genetic test to analyze genetic variations associated with inflammation and identify individuals with risk for periodontal disease. The company also provides weight management, bone health, heart health, nutritional needs, and wellness select genetic tests under the Inherent Health brand. It is also involved in the development of osteoarthritis genetic tests to detect adult joint diseases. The company markets its Inherent Health brand of genetic tests through its e-commerce Website, and under contract with Amway and various regional weight management focused organizations. It has clinical research collaborations with Stanford University, the University of North Carolina, the Mayo Clinic, Brigham & Women’s Hospital, University of California, New York University Medical Center, University of Sheffield, Yonsei University Medical Center, Tongji Medical College, Tuft’s University Medical Center, and Geisinger Clinic for the research and development of genetic tests. The company was founded in 1986 and is based in Waltham, Massachusetts.

interleukin genetics inc (ILIU) Top Compensated Officers

Founder, President, Chief Scientific Officer,...
Total Annual Compensation: $401.4K
Chief Financial Officer
Total Annual Compensation: $66.9K
Chief Marketing Officer
Total Annual Compensation: $290.8K
Compensation as of Fiscal Year 2014.

interleukin genetics inc (ILIU) Key Developments

Interleukin Genetics, Inc. Files Certificate of Amendment with the Secretary of State of the State of Delaware

On July 21, 2015, the Interleukin Genetics, Inc. filed a certificate of amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares of the company's common stock from 300,000,000 to 450,000,000. The certificate of amendment became effective upon filing.

Interleukin Genetics, Inc. Signs License Agreement to Develop the First Genetic Test of Its Kind

Interleukin Genetics, Inc. announced they signed a license agreement to develop the first genetic test of its kind to identify individuals at increased risk for progression of osteoarthritis (OA) and related complications, such as knee replacement. The agreement pertains to U.S. patent application No. 12/435,260 titled Detecting Genetic Predisposition to Osteoarthritis Associated Conditions, which is jointly owned by NYU School of Medicine and Interleukin Genetics. OA is the most common adult joint disease, increasing in frequency and severity in all aging populations. The estimated prevalence in the United States is 20-40 million patients; five times that of rheumatoid arthritis (RA). Severe forms of OA often lead to joint replacement surgery.

Interleukin Genetics, Inc. Proposes Amendment to its Restated Certificate of Incorporation

Interleukin Genetics, Inc. proposed an amendment to its restated certificate of incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 at any time prior to the earlier of August 1, 2016 and the 2016 annual meeting of stockholders, at its annual general meeting will be held on July 21, 2015. The company proposed an amendment to its restated certificate of incorporation to effect a reverse stock split by combining outstanding shares of its common stock into a lesser number of outstanding shares by a ratio of not less than 1-for-5 and not more than 1-for-40 at any time prior to the earlier of August 1, 2016 and the 2016 annual meeting of stockholders, with the exact ratio to be set within this range by its Board of Directors in its sole discretion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILIU:US $0.12 USD -0.0331

ILIU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILIU.
View Industry Companies

Industry Analysis


Industry Average

Valuation ILIU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.0x
Price/Book 9.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERLEUKIN GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at